Inactive Instrument

Audentes Therapeutics, Inc. Share Price

US05070R1041

Biotechnology & Medical Research

Latest news: Audentes Therapeutics, Inc.

14/24/14	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI
08/22/08	Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
21/22/21	Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
25/20/25	Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	CI
21/20/21	Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	CI
21/20/21	Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	CI
19/20/19	Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	CI
15/20/15	Audentes Therapeutics, Inc. Announces Management Changes	CI
15/20/15	Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	CI
15/20/15	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	CI
15/20/15	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	CI
15/20/15	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	CI
14/20/14	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	CI

More news

Press Releases: Audentes Therapeutics, Inc.

15/20/15	AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/19/17	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	BU
16/19/16	AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
03/19/03	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	PR
03/19/03	AUDENTES THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

News in other languages: Audentes Therapeutics, Inc.

04/19/04	NASDAQ COMPOSITE : Wall Street poursuit son repli, un accord USA-Chine s'éloigne
03/19/03	DOW JONES 30 : Wall Street ouvre dans le rouge, un accord USA-Chine s'éloigne
03/19/03	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
03/19/03	USA-Les valeurs à suivre à Wall Street (actualisé)
03/19/03	Astellas Pharma : Pharmakonzern Astellas kauft für 3 Mrd Dollar US-Gentherapiespezialisten

More news

Managers and Directors: Audentes Therapeutics, Inc.

Manager	Title	Age	Since
Morten Sogaard PSD	President	-	-
Jason Schwartz CTO	Chief Tech/Sci/R&D Officer	-	01/06/2022
David Smethurst LAW	General Counsel	-	01/08/2021

Director	Title	Age	Since
Alan Beggs BRD	Director/Board Member	-	-
Kush Parmar BRD	Director/Board Member	45	01/07/2013

More insiders

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/01/20	Louis Lange	Tender	Director	3,68,575	0.8037%
15/01/20	Jennifer Jarrett	Issuer sale	Director	53,200	0.1160%
15/01/20	Thomas Soloway	Tender	Chief Financial Officer	4,07,257	0.8881%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AUDENTES THERAPEUTICS, INC.	-.--%	-0.03%	-	-	277.49Cr
WUXI APPTEC CO., LTD.	+2.41%	-6.33%	+43.43%	+71.02%	6.33TCr
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	5.49TCr
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	5.33TCr
IQVIA HOLDINGS INC.	+0.03%	+4.59%	+26.94%	+51.95%	4.58TCr
BEONE MEDICINES AG	-1.12%	+2.30%	+21.78%	+123.77%	4.35TCr
REVOLUTION MEDICINES, INC.	+0.45%	+5.65%	+251.83%	+924.35%	4.02TCr
CELLTRION, INC.	+0.05%	+6.75%	+14.48%	+56.75%	3.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-5.84%	+27.86%	-0.65%	2.37TCr
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	2.38TCr
Average	+0.30%	+0.33%	+49.32%	+157.90%	4.24TCr
Weighted average by Cap.	+0.42%	+0.55%	+47.69%	+159.63%

Audentes Therapeutics, Inc. Share Price

Stocks

US05070R1041

Biotechnology & Medical Research

Latest news: Audentes Therapeutics, Inc.

Press Releases: Audentes Therapeutics, Inc.

News in other languages: Audentes Therapeutics, Inc.

Managers and Directors: Audentes Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile